Nikem Research and Dualsystems Biotech have joined forces to jointly offer their respective drug/target profiling and drug discovery services to their clients.

The alliance will combine Nikem’s synthetic and medicinal chemistry expertise, ADMET and DMPK, and early toxicology services with Dualsystem’s proprietary suite of technologies for drug and target profiling from a client’s phenotype assays.

As a single point of contact, the alliance will help clients speed drug development by providing real-time information about drug candidates, their targets and their mechanisms of action, and allow for a seamless downstream development of the molecules of interest.